Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(15%)

Phase Distribution

Ph phase_2
10
77%
Ph not_applicable
1
8%
Ph phase_1
1
8%
Ph phase_3
1
8%

Phase Distribution

1

Early Stage

10

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
10(76.9%)
Phase 3Large-scale testing
1(7.7%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Withdrawn2
unknown2
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (7.7%)
Phase 210 (76.9%)
Phase 31 (7.7%)
N/A1 (7.7%)

Trials by Status

withdrawn215%
completed646%
unknown215%
not_yet_recruiting18%
terminated215%

Recent Activity

0 active trials
Showing 5 of 13
not_yet_recruitingphase_2

PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure

NCT07619898
withdrawnphase_2

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
withdrawnphase_2

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

NCT03563040
terminatedphase_3

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
terminatedphase_2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07619898Phase 2

PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure

Not Yet Recruiting
NCT06646016Phase 2

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

Withdrawn
NCT03563040Phase 2

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

Withdrawn
NCT02524847Phase 3

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Terminated
NCT02322190Phase 2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Terminated
NCT00054600Phase 2

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease

Completed
NCT00054613Phase 2

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Completed
NCT00639717Phase 2

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Completed
NCT00221000Phase 2

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

Completed
NCT00030589Phase 2

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Unknown
NCT00930566Phase 1

Extracorporal Photopheresis Pilot Study

Unknown
NCT00004359Phase 2

Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

Completed
NCT00002011Not Applicable

The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13